GH Research PLC
GHRS14.270USD
-2.420-14.50%
Market hours （ET）Quotes delayed by 15 min
885.14MMarket Cap
LossP/E TTM
More Details of GH Research PLC Company
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Company Info
Ticker SymbolGHRS
Company nameGH Research PLC
IPO dateJun 25, 2021
Founded at2021
CEODr. Velichka (Villy) Valcheva, M.D.
Number of employees50
Security typeOrdinary Share
Fiscal year-endJun 25
AddressJoshua Dawson House
CityDUBLIN
Stock exchangeNASDAQ Global Market Consolidated
CountryIreland
Postal codeD02 RY95
Phone35314378334
Website
Ticker SymbolGHRS
IPO dateJun 25, 2021
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
11.20%
Lynx1 Capital Advisors LLC
10.39%
Terwey (Theis)
9.98%
Other
30.31%
Shareholders
Shareholders
Proportion
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
11.20%
Lynx1 Capital Advisors LLC
10.39%
Terwey (Theis)
9.98%
Other
30.31%
Shareholder Types
Shareholders
Proportion
Individual Investor
33.88%
Hedge Fund
24.16%
Investment Advisor
18.53%
Venture Capital
12.14%
Investment Advisor/Hedge Fund
9.67%
Research Firm
4.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
81
63.75M
102.78%
+7.18M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
2023Q1
76
51.21M
98.45%
-5.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
-1.57M
-15.12%
Mar 31, 2025
RA Capital Management, LP
6.94M
11.2%
+257.96K
+3.86%
Mar 31, 2025
Lynx1 Capital Advisors LLC
6.44M
10.39%
+90.87K
+1.43%
Mar 31, 2025
Terwey (Theis)
6.19M
9.98%
--
--
Dec 31, 2024
RTW Investments L.P.
5.50M
8.87%
+2.17M
+65.30%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.25M
6.85%
+1.76M
+70.85%
Mar 31, 2025
Cormorant Asset Management, LP
2.01M
3.24%
+1.42M
+238.84%
Mar 31, 2025
Deep Track Capital LP
2.00M
3.22%
+2.00M
--
Mar 31, 2025
TD Securities, Inc.
1.97M
3.17%
+1.97M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
AdvisorShares Psychedelics ETF
4.37%
iShares MSCI Ireland ETF
0.9%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
Proportion4.37%
iShares MSCI Ireland ETF
Proportion0.9%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
SPDR S&P International Small Cap ETF
Proportion0.02%
ALPS Medical Breakthroughs ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
